Target Deconvolution and Target Discovery

HuProt for Identifying Specific Molecular Targets

Understand the mechanism of action of the compound and its' effects on biological pathways

Target deconvolution is a process in drug discovery and development that involves identifying the specific molecular target(s) of a monoclonal or polyclonal antibody, bioactive compound or drug candidate. This process is crucial for understanding the mechanism of action of the compound, elucidating its effects on biological pathways, and assessing its potential therapeutic applications.

In disease research, it is not uncommon to identify antibodies without initially knowing their specific target. Monoclonal antibodies with unknown targets may have therapeutic potential for treating diseases or conditions for which the target antigen is unknown or poorly characterized. Further investigation and target identification efforts may reveal novel therapeutic opportunities based on the antibody's binding properties and biological effects.

In the featured publication below, HuProt™ microarray and VirScan® PhIP-Seq were used in the featured publication which demonstrated high-affinity molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and the central nervous system protein glial cell adhesion molecule (GlialCAM) and provided structural and in vivo functional evidence for its relevance. The results provide a mechanistic link for the association between MS and EBV and could guide the development of new MS therapies.

Featured Publication

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM

Tobias V. Lanz, William H. Robinson, et. al.

Abstract

Multiple sclerosis (MS) is a heterogenous autoimmune disease in which autoreactive lymphocytes attack the myelin sheath of the central nervous system. B lymphocytes in the cerebrospinal fluid (CSF) of patients with MS contribute to inflammation and secrete oligoclonal immunoglobulins. Epstein–Barr virus (EBV) infection has been epidemiologically linked to MS, but its pathological role remains unclear. Here we demonstrate high-affinity molecular mimicry between the EBV transcription factor EBV nuclear antigen 1 (EBNA1) and the central nervous system protein glial cell adhesion molecule (GlialCAM) and provide structural and in vivo functional evidence for its relevance.

VIEW PAPER

CDI Labs Advantages

The most comprehensive protein collections available allow for rapid proteome wide antibody repertoire analysis and target identification studies.

HuProt™ Proteome Microarrays provide high quality, reproducible results with a protein purification process that only selects properly folded proteins.

GMP/GLP compliant workflows and highly trained technicians ensure the highest quality results. Compliant data management processes ensure data integrity and security.

Cutting-edge synthetic biology platforms and an innovative team with deep proteomics bench expertise make CDI Labs an ideal CRO partner for even your most challenging projects.

HuProt Sample Requirements

Human serum or plasma

One 20 μL per sample

Antibody isolates

10 μg per sample (concentration 0.1 mg/mL)

Human cerebrospinal fluid (CSF)

Minimum 1.5 mL per sample

Protein / peptide / small molecule

10 μg per sample (concentration 0.1 mg/mL)

RNA

1 mL per sample (concentration 2 μM)

Other fluids

> Please contact us

PhiP-Seq Sample Requirements

Serum or plasma

20 μL aliquot per sample

Cerebrospinal fluid (CSF)

250 μL aliquot per sample

Other antibodies (IgG monoclonals, B cell supernatants, etc)

250 μL aliquot per sample (0.1 mg/mL concentration)

12 sample minimum

In multiples of x12 samples (i.e., x12, x24, x36, 48x – full rows of a standard 96-well plate), and any number after 48 samples